Despite not finding a direct association with prognosis, the fact that CD99 is detectable in most glioblastoma cases, along with the preclinical evidence supporting its role in glioblastoma pathogenesis and progression, suggests that it could still serve as a potential therapeutic target. This evidence concerns the gene CD99 and glioblastoma.